PDCD1 and neoplasm: Pembrolizumab is a humanized IgG4 monoclonal antibody developed by Merck & Co. that targets programmed cell death protein 1 (PD-1), a receptor expressed on activated T cells that downregulates immune responses and facilitates tumor immune evasion [116,117].